World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
110
Citations
54696
World Ranking
5473
National Ranking
2949

Robert A. Wolff publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Robert A. Wolff sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 596 publications — 71st percentile

71% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Robert A. Wolff D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Robert A. Wolff sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 110 D-Index — 73rd percentile

73% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Robert A. Wolff is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research focuses extensively on oncology, particularly pancreatic and hepatic oncology, with considerable contributions in cancer genomics and diagnostics, colorectal cancer, and cancer immunotherapy.

The scientist's work spans multiple fields, predominantly medicine and biochemistry, genetics, and molecular biology. Their subfields include oncology, cancer research, pulmonary and respiratory medicine, surgery, and epidemiology.

Robert A. Wolff publishes frequently in well-recognized academic venues. The most common publication outlets include:

  • Journal of Clinical Oncology
  • Cancer Research
  • Cancers
  • The Oncologist
  • Regular and Young Investigator Award Abstracts

Among their recent papers are:

  • "Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology" (2021), published in Journal of the National Comprehensive Cancer Network
  • "A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group" (2020), published in The Oncologist
  • "Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial" (2022), published in Nature Medicine
  • "CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study" (2020), published in The Lancet Oncology
  • "Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group" (2023), published in Journal of Clinical Oncology

They collaborate frequently with several researchers, including:

  • Michael J. Overman
  • Shubham Pant
  • Matthew H. G. Katz
  • Anirban Maitra
  • Jason Willis

Main topics covered by Robert A. Wolff include:

  • Pancreatic and Hepatic Oncology Research
  • Cancer Genomics and Diagnostics
  • Colorectal Cancer Treatments and Studies
  • Cancer Immunotherapy and Biomarkers
  • Neuroendocrine Tumor Research Advances
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Genetic factors in colorectal cancer

Best Publications

  • Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

    Malcolm J. Moore;David Goldstein;John Hamm;Arie Figer

  • Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer

    Navneet Dhillon;Bharat B. Aggarwal;Robert A. Newman;Robert A. Wolff

  • Pancreatic adenocarcinoma, version 2.2017: Clinical practice guidelines in Oncology

    Margaret A. Tempero;Mokenge P. Malafa;Mahmoud Al-Hawary;Horacio Asbun

  • Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy

    Gauri R. Varadhachary;Eric P. Tamm;James L. Abbruzzese;Henry Q. Xiong

  • Borderline resectable pancreatic cancer: the importance of this emerging stage of disease.

    Matthew H.G. Katz;Peter W.T. Pisters;Douglas B. Evans;Charlotte C. Sun

  • Pancreatic adenocarcinoma, Version 2.2021

    Margaret A. Tempero;Mokenge P. Malafa;Mahmoud Al-Hawary;Stephen W. Behrman

  • Preoperative Gemcitabine-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreatic Head

    Douglas B. Evans;Gauri R. Varadhachary;Christopher H. Crane;Charlotte C. Sun

  • Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study

    James C. Yao;Alexandria T. Phan;David Z. Chang;Robert A. Wolff

  • Fluorouracil, Doxorubicin, and Streptozocin in the Treatment of Patients With Locally Advanced and Metastatic Pancreatic Endocrine Carcinomas

    Maria A. Kouvaraki;Jaffer A. Ajani;Paulo Hoff;Robert Wolff

  • A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group.

    Humaid O. Al-Shamsi;Waleed Alhazzani;Ahmad Alhuraiji;Eric A. Coomes

  • Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point After Resection of Hepatic Colorectal Metastases

    Dan G. Blazer;Yoji Kishi;Dipen M. Maru;Scott Kopetz

  • Cetuximab, a Monoclonal Antibody Targeting the Epidermal Growth Factor Receptor, in Combination With Gemcitabine for Advanced Pancreatic Cancer: A Multicenter Phase II Trial

    Henry Q. Xiong;Arthur Rosenberg;Albert LoBuglio;William Schmidt

  • Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma

    Chandrajit P. Raut;Jennifer F. Tseng;Jennifer F. Tseng;Charlotte C. Sun;Huamin Wang

  • Pancreaticoduodenectomy with vascular resection: margin status and survival duration

    Jennifer F. Tseng;Chandrajit P. Raut;Jeffrey E. Lee;Peter W.T. Pisters

  • Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the M. D. Anderson Cancer Center experience

    Nora A Janjan;Vincent S Khoo;James Abbruzzese;Richard Pazdur

  • Long-Term Survival After Multidisciplinary Management of Resected Pancreatic Adenocarcinoma

    Matthew Harold Katz;Matthew Harold Katz;Huamin Wang;Jason B Fleming;Charlotte C Sun

  • Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators

    Matthew Harold Katz;Jason B Fleming;Priya R Bhosale;Gauri R Varadhachary

  • Preoperative Gemcitabine and Cisplatin Followed by Gemcitabine-Based Chemoradiation for Resectable Adenocarcinoma of the Pancreatic Head

    Gauri R. Varadhachary;Robert A. Wolff;Christopher H. Crane;Charlotte C. Sun

  • Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance.

    Scott Kopetz;Paulo M. Hoff;Jeffrey S. Morris;Robert A. Wolff

  • Cetuximab, a Monoclonal Antibody Targeting the Epidermal Growth Factor Receptor, in Combination With Gemcitabine for Advanced Pancreatic Cancer: A

    Henry Q. Xiong;Arthur Rosenberg;Albert LoBuglio;William Schmidt

Frequent Co-Authors

James L. Abbruzzese
James L. Abbruzzese Duke University
Michael J. Overman
Michael J. Overman The University of Texas MD Anderson Cancer Center
Christopher H. Crane
Christopher H. Crane Memorial Sloan Kettering Cancer Center
Douglas B. Evans
Douglas B. Evans Medical College of Wisconsin
Cathy Eng
Cathy Eng Vanderbilt University
Milind Javle
Milind Javle The University of Texas MD Anderson Cancer Center
Jeffrey E. Lee
Jeffrey E. Lee The University of Texas MD Anderson Cancer Center
Jason B. Fleming
Jason B. Fleming The University of Texas MD Anderson Cancer Center
Peter W.T. Pisters
Peter W.T. Pisters The University of Texas MD Anderson Cancer Center
Huamin Wang
Huamin Wang The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

While pursuing a Medical Doctor (MD) degree is a popular choice, there are many alternative career pathways in healthcare available through online programs. These options offer flexibility, affordability, and the opportunity to advance your career or specialize in related fields.

If you’re interested in healthcare leadership, consider pursuing one of the cheapest mha programs online. A Master’s in Healthcare Administration can prepare you for top management roles in hospitals and clinics.

For nurses looking to move into advanced clinical or leadership positions, the best online dnp programs provide a pathway to a terminal practice degree with hybrid and fully online options available.

Pharmacy is another in-demand field. The 3-year online pharmd programs allow working professionals or recent graduates to earn a Doctorate in Pharmacy efficiently, preparing them for clinical or research roles.

Lastly, healthcare technology is growing rapidly. A bachelor of health information management online can position you for vital roles in managing patient data and supporting hospital information systems.

Best Scientists Citing Robert A. Wolff

Trending Scientists

Recently Published Articles